The Tufts Center for the Study of Drug Development found that the average annual number of therapeutic peptides used in clinical trials increased from 9.7 during the 1990s to 16.9 between 2000 and 2007. "Therapeutic peptides have emerged as a therapeutically and commercially important class of drugs, and 48 are now on the market worldwide, with four having generated global sales of more than $500 million each in 2007," the study author said.

Related Summaries